To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

Summary

This will be a randomized, double blind, three-arm, single dose, parallel group, PK, PD and safety and immunogenicity study in healthy, adult, subjects. Total 306 healthy, adult, eligible human subjects (102 in each treatment arm) will be enrolled in the study with their consent. Required \*standby subjects will also be enrolled to ensure that 306 subjects are dosed in the study. The study will be conducted in cohorts; all the study procedures will be identical as mentioned in the protocol for all the cohorts.

Timeline

Start

2022-07-07

Primary completion

2023-02-21

Completion

2023-06-30

Drugs

Indications

No indication recorded.